GSK Wins Japan's Orphan Drug Designation for Velzatinib in Gastrointestinal Stromal Tumor

MT Newswires · 2d ago
02:49 AM EST, 11/19/2026 (MT Newswires) -- GSK (GSK.L) secured orphan drug designation for velzatinib as a treatment for gastrointestinal stromal tumor, or GIST, in Japan, according to a Thursday release. The designation from the Japanese Ministry of Health Labour and Welfare was based on the UK-listed drugmaker's ongoing phase 1/1b Strategist 1 study in people with advanced GIST, in which velzatinib demonstrated "promising" anti-tumor activity and tolerability profile. GSK is also evaluating velzatinib in late-stage studies as a first- and second-line treatment for advanced or metastatic GIST. Patient enrollment for the second-line treatment setting is ongoing, with data expected to be available in the second half.